Medicinal Cannabis & Sativex

posted by on March 20th 2012

Results from a phase III clinical study published online in the European Journal of Neurology Early View showed that about half of all people with moderate to severe spasticity due to multiple sclerosis (MS) who have not responded adequately to standard anti-spasticity therapy, find that adding Sativex Oromucosal Spray (delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD)), to their existing medication can improve the debilitating symptoms of spasticity associated with MS.

The primary efficacy endpoint was the change in a validated, 10 point (0-10) self-reported spasticity numerical rating scale (NRS) from the point of randomisation to the end of the treatment. Sativex was shown to provide significant improvement, compared to placebo, in the NRS spasticity score, spasm frequency and sleep disturbance related to spasticity.


Studying cannabis and its effects since 1995, educating the masses ever since.
Did you like this article?

Keep yourself up-to-date by subscribing to our blog feed!

Leave a Comment


Your email address will not be published. Required fields are marked *